Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

Recruiting

Observational StudyStudy of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

Sponsor:

Dana-Farber Cancer Institute

Code:

NCT02269592

Conditions

Monoclonal Gammopathy of Undetermined Significance (MGUS)

Myelodysplastic Syndromes

Hematological Malignancies

B-cell Malignancy, Low-grade

Myelodysplastic Syndrome With Low-grade Lesions

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-05-02. This information was provided to ClinicalTrials.gov by Dana-Farber Cancer Institute on 2026-02-12.